Custom-Made vaccine aims to stop esophageal Cancer's return
NCT ID NCT05307835
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a personalized vaccine made from a patient's own tumor proteins. The goal is to see if it's safe and can help prevent esophageal cancer from coming back after surgery and standard therapy. 27 patients who have completed initial treatments will receive the vaccine along with an immune booster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Personalized neoantigen vaccine (iNeo-Vac-P01) plus immune adjuvant (GM-CSF)
What this could lead to
If it works, this could offer a new way to prevent esophageal cancer from coming back after surgery and standard treatments.
What could go wrong
This is a very early (Phase 1) and small study with only 27 people. The vaccine is personalized, so it's complex and may not work for everyone. Side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China